CCL17 and melanoma: In some cancers, an increased expression of CCR4 ligands (CCL17 and CCL22) in a tumor may play an anti-tumor role in colon carcinoma [212], lung cancer [271], ovarian cancer [272] and melanoma [211,272], resulting in an increase in CD4+ T cells and CD8+ T cells.